机译:12周基于干扰素的达诺普韦疗法对基因型1型慢性丙型肝炎患者的疗效和安全性
Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing China;
The Sixth People's Hospital of Shenyang Shenyang Liaoning China;
People's Hospital of Jiangsu Province Nanjing Jiangsu China;
Beijing Friendship Hospital Capital Medical University Beijing China;
Nanjing Medical University Affiliated Second Hospital Nanjing Jiangsu China;
Liuzhou People's Hospital Liuzhou China;
Liver Disease Center of PLA The 81st Hospital of PLA Nanjing Jiangsu China;
Tangdu Hospital Air Force Medical University Xi'an Shaanxi China;
Baoji Central Hospital Baoji Shaanxi China;
The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China;
The First Hospital Affiliated to Jilin University Changchun Jilin China;
People's Hospital of Henan Province Henan China;
The First Hospital of Changsha Changsha Hunan China;
The First Affiliated Hospital of Guangxi Medical University Nanning Guangxi China;
The First Hospital of Hebei Medical University Shijiazhuang Hebei China;
Beijing Ditan Hospital Capital Medical University Beijing China;
Ascletis Bio Science Co. Ltd. Hangzhou Zhejiang China;
West China Hospital Sichuan University Chengdu Sichuan China;
Peking University People's Hospital Beijing China;
Xiangya Hospital of Central South University Changsha Hunan China;
Guangzhou Eighth People's Hospital Guangzhou Guangdong China;
Artificial Liver Center Beijing YouAn Hospital Capital Medical University Beijing China;
Huashan Hospital Fudan University Shanghai China;
The Third Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong China;